// STATE LEGISLATION TRACKER

California SB 861: Consumer affairs.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: California
Bill: SB 861
Session: 20252026
Filed: 2025-03-13
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

California SB861 is a broad consumer-affairs omnibus bill making technical and clarifying changes across several licensing and consumer programs. It does not appear to change peptide access, compounding rules, off-label prescribing, telehealth practice, NP or naturopath scope, controlled substances, or prescription monitoring.

Key Points

No direct peptide, compounding, or prescribing changes identified
No apparent change to 503A or 503B pharmacy rules
No apparent change to NP or naturopath peptide-prescribing scope
No apparent telehealth expansion or restriction for peptide care
Some licensing transparency and cleanup changes affect unrelated boards

What to Watch For

Note This is mainly a cleanup bill for Department of Consumer Affairs programs, not a peptide-access bill.

Note Clinicians should not treat this as new authority for compounded or off-label peptide prescribing.

Note No apparent change to controlled-substance monitoring or prescription database duties.

Where the Bill Stands

The bill was approved by the Governor and chaptered by the Secretary of State as Chapter 592, Statutes of 2025.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws